Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
The tumor suppressor protein p53 is known to induce either apoptosis or growth arrest depending on cellular background. We have previously reported that a bacterial redox protein azurin induces apoptosis in J774 cell line-derived macrophages whereas a site-directed mutant M44KM64E azurin shows very little cytotoxicity and fails to induce apoptosis in J774 cells. We now report that purified M44KM64E mutant azurin protein can enter both J774 cells as well as the human breast cancer MCF-7 cells. Entry of M44KM64E mutant azurin in J774 cells causes strong inhibition of cell-cycle progression at the G 1 to S phase and a higher level of transcription of the p21 gene. Corresponding to high p21 levels, the levels of cyclins and cyclin-dependent kinases were greatly lowered in M44KM64E mutant azurin-treated J774 cells. Interestingly, M44KM64E mutant azurin protein failed to elicit inhibition of cell-cycle progression in MCF-7 cells, presumably because of mutation at the retinoblastoma tumor suppressor protein that allows functional E2F formation in MCF-7 cells even in the presence of high intracellular p21 level. Thus, the WT azurin induces apoptosis but little inhibition of cell-cycle progression whereas the M44KM64E mutant azurin is deficient in the induction of apoptosis but mediates strong inhibition of cell-cycle progression, demonstrating the role of a single bacterial protein and its hydrophobic patch in modulating two important functions of p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, E. coli has been shown to colonize the region surrounding the necrotic core of tumors after intravenous injection9, and several reports have demonstrated the use of engineered E. coli strains to treat solid tumors in preclinical models15,62–65.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Zhang et al. developed a strain of EcN to express azurin, a small bacterial protein that induces apoptosis in tumor cells62. This engineered strain suppressed the growth of tumors and prevented pulmonary metastasis in mice63.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,422
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
NPAT links cyclin E–Cdk2 to the regulation of replication-dependent histone gene transcription
Zhao, J., Kennedy, B. K., Lawrence, B. D., Barbie, D. A., Matera, A. G., Fletcher, J. A., & Harlow, E. (2000) · Genes & Development · doi:10.1101/gad.827700 · Cited by 665
Mechanisms of p53-dependent apoptosis
Schuler, M., & Green, D. R. (2001) · Biochemical Society Transactions · doi:10.1042/bst0290684 · Cited by 641
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H., & Levine, A. J. (2000) · Genes & Development · doi:10.1101/gad.14.8.981 · Cited by 634
p21WAF1/Cip1: more than a break to the cell cycle?
Dotto, G. P. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00019-6 · Cited by 474
Research works printed but not linked: 5
- Dotto, G. P. (2000) Biochim. Biophys. Acta 1471, M43–M56. [DOI] [PubMed] [Google Scholar]
- Sherr, C. J. (2000) Cancer Res. 60, 3689–3695. [PubMed] [Google Scholar]
- Asher, G., Lotem, J., Cohen, B., Sachs, L. & Shaul, Y. (2001) Proc. Natl. Acad. Sci. USA, 98, 1188–1193. [DOI] [PMC free article] [PubMed] [Google Scholar] · doi:10.1073/pnas.98.3.1188 · Paper page
- Punj, V., Bhattacharyya, S., Saint-Dic., D., Vasu, C., Cunningham, E. A., Graves, J., Yamada, T., Constantinou, A. I., Christov, K., White, B., et al. (2004) Oncogene 23, 2363–2374. [DOI] [PubMed] [Google Scholar]
- Zhou, J.-N. & Linder, S. (1996) Anticancer Res. 16, 1931–1936. [PubMed] [Google Scholar]
Cited by
ROS and p53: A versatile partnership
Liu, B., Chen, Y., & St. Clair, D. K. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.01.011 · Cited by 830
“In pathogenic bacterium Pseudomonas aeruginosa induced cell death, azurin, a copper-containing redox protein excreted by Pseudomonas aeruginosa binds to p53 and transactivates pro-apoptosis protein Bax, leading to apoptosis [64,65].”
BackgroundBacteriocins as a new generation of antimicrobials: toxicity aspects and regulations
Soltani, S., Hammami, R., Cotter, P. D., Rebuffat, S., Said, L. B., Gaudreau, H., Bédard, F., Biron, E., Drider, D., & Fliss, I. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa039 · Cited by 544
“aeruginosa strain, was studied as a potential anticancer drug due to its selective binding to human cancer cells, and resultant cytotoxic and apoptotic effects, without apparently affecting normal cells (Yamada et al. 2004).”
BackgroundDeveloping a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells
Taylor, B. N., Mehta, R. R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A. M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2932 · Cited by 184
Self-citationDuraj‐Thatte, A., Manjula‐Basavanna, A., Rutledge, J., Xia, J., Hassan, S., Sourlis, A., Rubio, A. G., Lesha, A., Zenkl, M., Kan, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26791-x · Cited by 148
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138
“It can be efficiently internalized in order to initiate cancer cell apoptosis by raising the intracellular levels of p53 and Bax, resulting in the release of mitochondrial cytochrome c into the cytosol (38).”
BackgroundA peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells
Yamada, T., Mehta, R. R., Lekmine, F., Christov, K., King, M. L., Majumdar, D., Shilkaitis, A., Green, A., Bratescu, L., Beattie, C. W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0444 · Cited by 114
“Fixed cells were washed with PBS and stained by 50 μg/mL propidium iodide in PBS containing 20 μg/mL RNase A (4).”
MethodSelf-citationMehta, R. R., Yamada, T., Taylor, B. N., Christov, K. T., King, M. L., Majumdar, D., Lekmine, F., Tiruppathì, C., Shilkaitis, A. L., Bratescu, L., et al. (2011) · Angiogenesis · doi:10.1007/s10456-011-9220-6 · Cited by 117
“Azurin and amino acids (aa) 50–77 (p28) of azurin preferentially penetrate and exert a p53-mediated cytostatic and apoptotic (cytotoxic) effect on human cancer cells with no apparent effect on normal cells [14–19, 33–36].”
BackgroundSelf-citationBernardes, N., & Fialho, A. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123871 · Cited by 115
Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions
Nhàn, N. T. T., Yamada, T., & Yamada, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612931 · Cited by 119
Self-citationYamada, T., Fialho, A. M., Punj, V., Bratescu, L., Gupta, T. K. D., & Chakrabarty, A. M. (2005) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00567.x · Cited by 107
Self-citationBacteria and bacterial derivatives as delivery carriers for immunotherapy
Kang, S., Nguyen, D.-H., Yoo, S. W., & Min, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114085 · Cited by 106
Microbial-based therapy of cancer: Current progress and future prospects
Bernardes, N., Seruca, R., Chakrabarty, A. M., & Fialho, A. M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.3.10903 · Cited by 92
Self-citationChaudhari, A., Mahfouz, M., Fialho, A. M., Yamada, T., Granja, A. T., Zhu, Y., Hashimoto, W., Schlarb-Ridley, B., Cho, W., Gupta, T. K. D., et al. (2007) · Biochemistry · doi:10.1021/bi061661x · Cited by 74
“... to EphB2 but significantly reduced its binding affinity with the EphA6 or EphA7 receptors (Figure 5, Table 4). Although previously believed to be involved only in electron transfer during denitrification by Pseudomonas aeruginosa, mutational studies did not show any such role of azurin (42), and it now appears tha…”
BackgroundSelf-citationDomenici, F., Bizzarri, A. R., & Cannistraro, S. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.10.010 · Cited by 72
“Indeed, cellular [30,31] and molecular studies [32,33] have demonstrated that Az is an exogenous vector able to preferentially enter cancer cells (such as in melanoma UISO-Mel-2 and breast cancer MCF-7 cells) and to form a specific and stable complex with the human p53 protein, thereby increasing its tumor suppressor…”
BackgroundJia, L., Gorman, G. S., Coward, L. U., Noker, P. E., McCormick, D. L., Horn, T. L., Harder, J. B., Muzzio, M., Prabhakar, B. S., Ganesh, B. B., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1518-3 · Cited by 71
“Azurin, a member of the cupredoxin family of copper containing, redox proteins preferentially penetrates human cancer cells and exerts cytostatic and cytotoxic (apoptotic) effects with no apparent activity on normal cells [5, 8, 9].”
Taranta, M., Bizzarri, A. R., & Cannistraro, S. (2008) · Journal of Molecular Recognition · doi:10.1002/jmr.869 · Cited by 69
Genetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
“Chowdhury et al. engineered an E. coli strain to release an anti-CD47 antagonist nanobody inducing tumor regression and abscopal efects and exhibiting long-term survival in a syngeneic tumor mouse model [185–188].”
BackgroundEngineering of bacterial strains and their products for cancer therapy
Bernardes, N., Chakrabarty, A. M., & Fialho, A. M. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4926-6 · Cited by 70
Self-citationGao, M., Zhou, J., Su, Z., & Huang, Y. (2017) · Protein Science · doi:10.1002/pro.3310 · Cited by 64
“Glycerol gradient centrifugation has shown that azurin forms complexes with full-length p53 (p53 FL), where p53 is a tetramer.(22,23) Therefore, one p53 tetramer is able to bind four azurin molecules.”
BackgroundSignificance of human microbiome in breast cancer: Tale of an invisible and an invincible
Chadha, J., Nandi, D., Atri, Y., & Nag, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.010 · Cited by 63
Docking study and free energy simulation of the complex between p53 DNA‐binding domain and azurin
De Grandis, V., Bizzarri, A. R., & Cannistraro, S. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.840 · Cited by 60
“These results make AZ an attractive candidate for developing novel anticancer strategies (Yamada et al., 2002, 2004; Punji et al., 2003; Punj et al., 2004; Apiyo and Wittung-Stafshede, 2005).”
BackgroundMethodInfluentialp28 Bacterial Peptide, as an Anticancer Agent
Yaghoubi, A., Khazaei, M., Avan, A., Hasanian, S. M., Cho, W. C. S., & Soleimanpour, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01303 · Cited by 59
Unique complex between bacterial azurin and tumor-suppressor protein p53
Apiyo, D. O., & Wittung-Stafshede, P. E. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.038 · Cited by 55
Hayano, S., Komatsu, Y., Pan, H., & Mishina, Y. M. (2015) · Development · doi:10.1242/dev.118802 · Cited by 57
“Additionally, the bacterial redox protein azurin is known to induce only p53-mediated apoptosis (Yamada et al., 2004).”
BackgroundBuilding Cell Selectivity into CPP-Mediated Strategies
Martín, I., Teixidò, M., & Giralt, E. (2010) · Pharmaceuticals · doi:10.3390/ph3051456 · Cited by 53
“Together, these peptides are not only capable of preferentially internalizing cancer cells, but can also exert a toxic effect on them and thereby prevent their proliferation.”
BackgroundPotent and Tumor specific: Arming Bacteria With Therapeutic Proteins
Dessel, N. V., Swofford, C. A., & Forbes, N. S. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.113 · Cited by 53
Bizzarri, A. R., Santini, Bucciantini, Agostino, D., Yamada, T., Beattie, & Cannistraro, S. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26155 · Cited by 47
“…well as computational studies have reported that azurin binds to either the NTD of p53 14,17,18 or its DBD. 14,19,20 Site-direct mutagenesis 12,13,15 and computational investigations 20 have revealed that the two methionines, located at positions 44 and 64 within a hydrophobic patch of azurin…”
InfluentialSelf-citationCross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression
Choi, J. K., Naffouje, S. A., Goto, M., Wang, J., Christov, K. T., Rademacher, D. J., Green, A., Stecenko, A. A., Chakrabarty, A. M., Gupta, T. K. D., et al. (2023) · Communications Biology · doi:10.1038/s42003-022-04395-5 · Cited by 51
Self-citationBacterial proteins and peptides in cancer therapy: Today and tomorrow
Chakrabarty, A. M., Bernardes, N., & Fialho, A. M. (2014) · Bioengineered · doi:10.4161/bioe.29266 · Cited by 49
Self-citationWang, X., Li, N., Li, H., Liu, B., Qiu, J., Chen, T., & Cao, X. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0879 · Cited by 48
Nguyen, C., & Nguyễn, V. D. (2016) · BioMed Research International · doi:10.1155/2016/8490482 · Cited by 43
“Azurin can preferentially penetrate human cancer cells and exerts cytostatic and apoptotic effects with no apparent activity on normal cells [7, 8].”
BackgroundSwofford, C. A., Jean, A. S., Panteli, J. T., Brentzel, Z. J., & Forbes, N. S. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25184 · Cited by 44
“Azurin is an oxidoreductase produced by bacteria that possesses the unique ability to form a complex with tumor suppressor p53, increasing its intracellular concentration and inducing apoptosis (Yamada et al., 2004).”
BackgroundGupta, A., Nishchaya, K., Saha, M., Naik, G. A. R. R., Yadav, S., Srivastava, S., Roy, A. A., Moorkoth, S., Mutalik, S., & Dhas, N. L. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105401 · Cited by 46
Perez-Henarejos, S. A., Alcaraz, L. A., & Donaire, A. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.08.020 · Cited by 40
SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor
Bizzarri, A. R. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s23845 · Cited by 39
“Indeed, cellular 32,33 and molecular studies 34,35 have demonstrated that azurin is an exogenous vector able to enter cancer cells preferentially and form a specific and stable complex with human p53, increasing its tumor suppressor activity.”
Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy
Shanmugaraj, B., Priya, L. B., Mahalakshmi, B., Subbiah, S., Hu, R., Velmurugan, B. K., & Baskaran, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117550 · Cited by 43
Bernardes, N., Ribeiro, A. S., Abreu, S. C., Mota, B., Matos, R. G., Arraiano, C. M., Seruca, R., Paredes, J., & Fialho, A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069023 · Cited by 39
Bernardes, N., Abreu, S. C., Carvalho, F. A., Fernandes, F., Santos, N. C., & Fialho, A. M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1172147 · Cited by 37
“Azurin, a protein from the bacterium Pseudomonas aeruginosa, has demonstrated antitumor properties.(7,8) This protein has been intensively studied in different in vitro and in vivo models, demonstrating its ability to interfere in different steps of tumor development.”
BackgroundAnticancer peptides from bacteria
Karpiński, T. M. M., & Szkaradkiewicz, A. K. (2013) · Bangladesh Journal of Pharmacology · doi:10.3329/bjp.v8i3.15704 · Cited by 35
“It has been shown that in p53 wild-type MCF-7 breast cancer cells, treatment with azurin caused an increase in p53 levels in both nuclear and cytoplasmic fractions (Punj et al., 2004; Yamada et al., 2004; Yamada et al., 2009).”
BackgroundMolecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function
Fu, T., Min, H., Xu, Y., Chen, J., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089709 · Cited by 34
Exploring the anticancer potential of the bacterial protein azurin
Fialho, A. M., Bernardes, N., & Chakrabarty, A. M. (2016) · AIMS Microbiology · doi:10.3934/microbiol.2016.3.292 · Cited by 32
“cells, azurin interferes in cell growth by multiple mechanisms including complex formation with the DNA-binding domain (DBD) of tumor suppressor protein p53 [13,16], stabilizing it and enhancing its intracellular level (both nuclear and cytoplasmatic fractions), which then allows induction of apoptosis [13].”
Self-citationHersi, F., Elgendy, S. M., Shamma, S. A. A., Altell, R. T., Sadiek, O., & Omar, H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120573 · Cited by 31
Bacterial azurin in potential cancer therapy
Chakrabarty, A. M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1179034 · Cited by 29
Self-citationHasanzadeh, M., & Shadjou, N. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.02.038 · Cited by 28
Modelling the interaction between the p53 DNA‐binding domain and the p28 peptide fragment of Azurin
Santini, S., Bizzarri, A. R., & Cannistraro, S. (2011) · Journal of Molecular Recognition · doi:10.1002/jmr.1153 · Cited by 29
“…action has been shown to be consequent to the interaction of Azurin with p53 that leads to both the stabilization and the intracellular level rise of the transcription factor (Yamada et al., 2002a; Yamada et al., 2002b; Goto et al., 2003; Punj et al., 2003; Punj et al., 2004; Yamada et al., 2004).”
BackgroundInfluentialDomenici, F., Frasconi, M., Mazzei, F., D’Orazi, G., Bizzarri, A. R., & Cannistraro, S. (2011) · Journal of Molecular Recognition · doi:10.1002/jmr.1105 · Cited by 32
“Several in vitro and in vivo studies have shown that the protein can enter cancer cells and induce their apoptotic death (Yamada et al., 2002, 2004, 2005; Punj et al., 2004).”
BackgroundBernardes, N., Ribeiro, A. S., Abreu, S. C., Vieira, A. F., Carreto, L. C., Santos, M. A. S., Seruca, R., Paredes, J., & Fialho, A. M. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.01.023 · Cited by 27
Modeling the interaction between the N‐terminal domain of the tumor suppressor p53 and azurin
Taranta, M., Bizzarri, A., & Cannistraro, S. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.934 · Cited by 28
“Recent works have demonstrated that the copper-containing protein azurin (AZ) from the bacterium Pseudomonas aeruginosa can enter some human cancer cells and interact with p53, stabilizing it and inducing apoptosis through its pathway (Yamada et al., 2004).”
BackgroundWang, H., Huang, Y., He, J., Zhong, L., & Zhao, Y. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13086 · Cited by 30
Bizzarri, A. R., Moscetti, I., & Cannistraro, S. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.11.003 · Cited by 23
Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review
Teveroni, E., Lucà, R., Pellegrino, M., Ciolli, G., Pontecorvi, A., & Moretti, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1233179 · Cited by 26
“This property has been related to the ability of Azurin to interact with p53, leading to its stabilization [43,45].”
BackgroundSilva, M., Monteiro, G. A., Fialho, A. M., Bernardes, N., & da Silva, C. L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00471 · Cited by 21
Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy
Mander, S., Naffouje, S. A., Gao, J., Li, W., Christov, K. T., Green, A., Bongarzone, E. R., Gupta, T. K. D., & Yamada, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940001 · Cited by 22
Self-citationYamada, T., Hiraoka, Y., Gupta, T. K. D., & Chakrabarty, A. M. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1125 · Cited by 21
Self-citationMicrobial based therapy of cancer: A new twist to an age old practice
Punj, V., Saint‐Dic, D., Daghfal, S., & Kanwar, J. R. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.964 · Cited by 22
Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin
Signorelli, S., Cannistraro, S., & Bizzarri, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123078 · Cited by 17
Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells
Paydarnia, N., Nikkhoi, S. K., Fakhravar, A., Mehdiabdol, M., Heydarzadeh, H., & Ranjbar, S. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04767-x · Cited by 17
Ultrafast Pump–Probe Study of the Excited-State Charge-Transfer Dynamics in Blue Copper Rusticyanin
Bizzarri, A. R., Brida, D., Santini, S., Cerullo, G., & Cannistraro, S. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp301484g · Cited by 16
Okal, A., Matissek, K. J., Matissek, S. J., Price, R., Salama, M. E., Janat-Amsbury, M.-M., & Lim, C. S. (2014) · Gene Therapy · doi:10.1038/gt.2014.70 · Cited by 15
Mehta, R. R., Hawthorne, M., Peng, X., Shilkaitis, A. L., Mehta, R. G., Beattie, C. W., & Gupta, T. K. D. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0024 · Cited by 15
Yamada, T., Hiraoka, Y., Gupta, T. K. D., & Chakrabarty, A. M. (2004) · Cell Cycle · doi:10.4161/cc.3.6.922 · Cited by 15
Self-citationBizzarri, A. R., Agostino, S. D., Andolfi, L., & Cannistraro, S. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.975 · Cited by 14
“These docking procedures have taken advantage from some information on possible interacting regions between DBD and AZ (Yamada et al., 2004; De Grandis et al., 2007).”
BackgroundDoes azurin bind to the transactivation domain of p53? A Trp phosphorescence study
Gabellieri, E., Bucciantini, M., Stefani, M., & Cioni, P. (2011) · Biophysical Chemistry · doi:10.1016/j.bpc.2011.07.008 · Cited by 14
A Method of Tumor In Vivo Imaging with a New Peptide-Based Fluorescent Probe
Naffouje, S. A., Goto, M., Ryoo, I., Green, A., Gupta, T. K. D., & Yamada, T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1811-0_45 · Cited by 12
“aeruginosa preferentially enters a variety of cancer cells and induces p53-mediated apoptosis [2-6].”
BackgroundSelf-citationCombination of bacteriolytic therapy with magnetic field for Ehrlich tumour treatment
Ali, F. M., El-Gebaly, R. H., & Hamad, A. M. (2017) · General Physiology and Biophysics · doi:10.4149/gpb_2016051 · Cited by 12
“Apoptosis induction of P. aeruginosa bacterium can be managed by producing several cytotoxic products inside the tumours; for example Azurin protein (Yamada et al. 2002, 2004) and P. aeruginosa exotoxin A (ETA) (Keppler-Hafkemeyer et al. 2000; Schmidt et al. 2001), as well as the activity of this…”
BackgroundÜnver, Y., Arslan, Ş. Y., & Acar, M. (2022) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-021-02678-5 · Cited by 11
“This situation is primarly related to its strong affinity to cellular tumor antigen p53, which is an important regulator of cell growth, cell death and genomic stability [9].”
BackgroundPromiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design
Fialho, A. M., & Chakrabarty, A. M. (2010) · Wiley eBooks · doi:10.1002/9780470626528.ch8 · Cited by 11
Self-citationYe, Z., Peng, H., Fang, Y., Feng, J., & Yang, D. (2007) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-007-0012-3 · Cited by 11
Breast cancer vaccination: Latest advances with an analytical focus on clinical trials
Vajari, M. K., Sanaei, M., Salari, S., Rezvani, A., Ravari, M. S., & Bashash, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110696 · Cited by 10
Ghasemi-Dehkordi, P., Doosti, A., & Jami, M. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.04.007 · Cited by 9
Structural studies on Laz, a promiscuous anticancer Neisserial protein
Hashimoto, W., Ochiai, A., Hong, C. S., Murata, K., & Chakrabarty, A. M. (2015) · Bioengineered · doi:10.1080/21655979.2015.1022303 · Cited by 9
“The complex formed by azurin and p53 as well as its electron transfer partner cytochrome c induces apoptosis in cancer cells through cell cycle arrest at the G1 phase or caspase-mediated mitochondrial cytochrome c release.(6,7) Azurin is therefore expected to be a potential drug for cancer therapy.”
BackgroundSelf-citationNguyễn, V. D., Nguyen, T. T., Pham, T. T., Packianather, M., & Le, C. H. (2019) · International Microbiology · doi:10.1007/s10123-019-00070-8 · Cited by 9
Barzelighi, H. M., Bakhshi, B., Daraei, B., & Mirzaei, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139245 · Cited by 9
Abedi, S., Doosti, A., & Jami, M. (2019) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2019.1660892 · Cited by 7
Nguyễn, V. D., & Nguyen, H. H. C. (2015) · Advances in intelligent systems and computing · doi:10.1007/978-3-319-17996-4_20 · Cited by 6
Bacterial protein azurin as a new candidate drug to treat untreatable breast cancers
Bernardes, N., Ribeiro, A. S., Seruca, R., Paredes, J., & Fialho, A. M. (2011) · IEEE Portuguese Meeting on Bioengineering · doi:10.1109/enbeng.2011.6026047 · Cited by 5
“After internalization, azurin forms a complex with the tumor suppressor protein p53, stabilizing it, and increasing its intracellular level, thereby inducing apoptosis via caspasemediated mitochondrial cytochrome c release pathways or cell cycle arrest at the G1 phase, depending on the cell types [3].”
BackgroundBIOINFORMATIC STUDY OF AN ANTITUMOR PROTEIN, AZURIN
Abiraami Valli, S., & Mythili, T. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i6.23339 · Cited by 5
Xu, C., Yin, J., & Zhao, B. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-4069-2 · Cited by 5
The interaction of azurin and C-terminal domain of p53 is mediated by nucleic acids
Xu, C., Zhao, Y., & Zhao, B. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.08.015 · Cited by 5
Iozzo, M., Vitali, F., Chiellini, C., Gammuto, L., Taddei, A., Amedei, A., & Fani, R. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2711305 · Cited by 4
Genetically engineered filamentous phage for bacterial detection using magnetic resonance imaging
Borg, R. E., Ozbakir, H. F., Xu, B., Li, E., Fang, X., Peng, H., Chen, I. A., & Mukherjee, A. (2023) · Sensors & Diagnostics · doi:10.1039/d3sd00026e · Cited by 4
Bacterial Protein Azurin and Tumour Suppressor P53 in Cancer Regression
Dharmawickreme, R. B. L., & Witharana, C. (2021) · Advances in Human Biology · doi:10.4103/aihb.aihb_69_20 · Cited by 4
Hiraoka, Y., Granja, A. T., Fialho, A. M., Schlarb‐Ridley, B. G., Gupta, T. K. D., Chakrabarty, A. M., & Yamada, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.078 · Cited by 4
“In contrast, a mutant form of azurin, the M44KM64E azurin, where two hydrophobic methionine residues on the surface were replaced by two charged amino acids, elicited little induction of apoptosis in J774 cells but triggered inhibition of cell cycle progression [ 15 ].”
BackgroundSelf-citationBizzarri, A. R., & Cannistraro, S. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c06778 · Cited by 3
p53 siRNA inhibits apoptosis of U2OS cells treated with azurin
Li, W. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.544 · Cited by 3
“However, the tumor suppressor protein p53 is known to either induce apoptosis or arrest growth depending on cellular background (12). p53 siRNA decreases p53 protein levels, and this decrease in p53 is capable of inhibiting cancer cell apoptosis.”
Ghasemi-Dehkordi, P., Doosti, A., & Jami, M. (2020) · Journal of Shahrekord University of Medical Sciences · doi:10.34172/jsums.2020.07 · Cited by 1
“This bacteriocin has cytostatic properties, can specifically penetrate into human cancer cells, and induces apoptosis but has no apparent activity in normal cells (17,18).”
BackgroundBacterial-based cancer therapy: mechanisms and therapeutic advances
Sharifi, A. H., Phong, N. H. T., Marek, A., Kamal, M. A., Al-Kodmany, S., Tran, D. B., & Yamada, T. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00524-2 · Cited by 1
“Other strategies use bacterial surface-display systems to present ligands or receptors that improve tumor-marker recognition and selective accumulation [184–187].”
Self-citationScreening and Identification of Microbial Derivatives for Inhibiting Legumain: An In silico Approach
Reddy, B. D., & Chitturi, C. M. K. (2018) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.12.3.69 · Cited by 1
用定点自旋标记的方法研究天青蛋白疏水区的结构及其与p53蛋白的相互作用
赵, 保., 殷, 俊., & 徐, 超. (2011) · Scientia Sinica Vitae · doi:10.1360/zc2011-41-1-30 · Cited by 1
P53 AND REACTIVE OXYGEN SPECIES: A CONVOLUTED STORY
Liu, B. (2007) · UKnowledge (University of Kentucky) · Cited by 2
Rasoamanana, H. (2022) · theses.fr (ABES) · doi:10.70675/34fe0d66z3df3z4b2azb07fz3e6636c7cc50 · Cited by 3
Discovering and exploiting bacterial proteins as anticancer agents
da Silva, G. E. F. M. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Garland, G. D., Patil, K. R., Turner, S. D., & Willis, A. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286741
EVALUATION OF ANTICANCER EFFECT OF RECOMBINANT AZURIN TOXIN ON BREAST CANCER CELL LINE
Saatlou, H. R., & Eimani, B. G. (2024) · Studies in Medical Sciences · doi:10.61186/umj.34.11.2
Application of Bacteriocins in Practice, Including Microcins: the Present and the Future
Теймуразов, М. Г., Kovalenko, I. M., & Khokhlova, O. E. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2024-69-9-10-71-85 · Cited by 1
Reddy, V. P. M. S., Sahu, R., Sasidharan, S., Khan, J. M., & Saudagar, P. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153235
Mohammed, O. A., Awlqadr, F. H., Faraj, A. M., Qadir, S. A., Morya, S., & Saeed, M. N. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12302-y
“In parallel, free azurin has been reported to interfere with oncogenic signaling nodes such as PI3K/AKT, Wnt/β-catenin, and VEGF-mediated angiogenic pathways, thereby suppressing tumor proliferation, migration, and vascularization [22, 36, 45, 58].”
Deeb, N., Otinov, G., Tikhomirov, A., Mouhammad, E., Savin, A., & Koshel, E. I. (2026) · Applied Microbiology · doi:10.3390/applmicrobiol6100126
Metadata
- Authors
- Yamada, T., Hiraoka, Y., Ikehata, M., Kimbara, K., Avner, B. S., Das Gupta, T. K., & Chakrabarty, A. M.
- Affiliations
- Railway Technical Research Institute (JP)
- Departments of Microbiology and Immunology and Surgical Oncology, University of Illinois, Chicago, IL 60612; and Environment Biotechnology Laboratory, Railway Technical Research Institute, Tokyo 185-8540, Japan
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-03-24
- Volume
- 101
- Issue
- 14
- Pages
- 4770-4775
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC387323
- OpenAlex
- W2165242628
- Cited by
- 98
- References
- 31
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 4 · 2020: 9 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 5 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (T32AI007343)
- National Institute of Environmental Health Sciences (ES-04050-18, R01ES004050)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- p53, azurin, apoptosis, cell cycle arrest, cyclin-dependent kinases, retinoblastoma protein, E2F transcription factors, hydrophobic patch, J774 macrophages, MCF-7 cells
- MeSH terms
- Azurin, Base Sequence, Humans, Oxidation-Reduction, Transcription, Genetic, Tumor Suppressor Protein p53, Cyclins, Apoptosis, DNA Primers, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.